Last updated: May 24, 2026
Meclizine hydrochloride is widely manufactured across multiple global commodity and specialty API producers, with finished-dose supply concentrated in branded and generic tablet and capsule channels. Supplier identification depends on whether you need the API (meclizine HCl) or the finished dosage form (tablets/capsules), plus the regulatory market (US, EU, etc.).
Which companies supply meclizine hydrochloride API (active pharmaceutical ingredient)?
Meclizine hydrochloride is typically supplied as an API under cGMP for generic drug manufacturing. API sources for meclizine HCl are commonly listed in drug master files (DMFs) and supplier qualification records tied to Abbreviated New Drug Applications (ANDAs). In practice, buyers validate through: DMF ownership, inspection history, particle control specs, residual solvent profile, impurity limits, polymorph control, and salt-form consistency.
Common API supplier archetypes
- Large-scale generics API manufacturers supplying high-volume antihistamine/antiemetic intermediates.
- Specialty API producers focused on hydrochloride salts and controlled impurity profiles.
- Contract API manufacturers offering synthesis-to-spec for meclizine HCl.
API vs. finished dosage form
- API buyers typically require US DMF or US CEP equivalence (EU), full impurity disclosure strategy, and batch traceability.
- Finished-dose buyers require ready-to-market documentation (CoA per batch, stability packs, labeling, and pharmacovigilance readiness).
What suppliers provide meclizine hydrochloride tablets and capsules (finished dosage forms)?
Finished meclizine hydrochloride supply for OTC and prescription channels is dominated by multi-product generic manufacturers. Product configurations include:
- Tablets (most common)
- Capsules (market-dependent)
- Typical strengths include 12.5 mg and 25 mg in US market generics
Buyer selection criteria for finished meclizine
- ANDA holder track record and CMC package completeness (bioequivalence study basis where applicable).
- Controlled blending and dissolution specs (meclizine is salt-based and sensitive to tablet disintegration and dissolution controls).
- Packaging configuration for channel (bottles, blister packs), shelf-life availability, and temperature excursion history.
Who manufactures meclizine hydrochloride in the US market (ANDA holders and generic brands)?
US supply is primarily driven by generic and OTC labelers. The practical way to map “who supplies” in the US is to pull meclizine HCl product listings from FDA’s Orange Book and then trace:
- Application holder (ANDA sponsor)
- Strength and dosage form
- Manufacturer of record on labeled product (varies by labeler)
- DMF-linked API manufacturer through CMC references
Because meclizine HCl is an established small-molecule with broad generic penetration, multiple ANDAs typically exist for each strength/dosage form, resulting in overlapping supply from different labelers and manufacturing sites.
What is the Orange Book status of meclizine hydrochloride products?
Answer: Meclizine hydrochloride products are generally available as multiple generics and OTC preparations with no meaningful active patent barriers that would materially restrict entry in modern channels.
Operational implication for suppliers
- Procurement is less constrained by patent exclusivity and more constrained by manufacturing capacity, quality system maturity, and supply reliability.
- Contract manufacturing and re-packaging are common in this category because finished products are relatively standardized.
(Orange Book listing verification is done per specific NDC/strength/dosage form because the status is product-specific.)
Which suppliers provide DMF-linked meclizine hydrochloride API for ANDA filings?
ANDA CMC packages often reference DMFs for API manufacturing. For meclizine hydrochloride, API sourcing for ANDA programs is typically traceable via DMF holder identity and the reference number in the CMC section.
How buyers identify API suppliers
- Confirm the DMF holder tied to the ANDA’s API manufacturing process.
- Request and audit: CoA template, impurity profile targets, residual solvents (ICH Q3C), and genotoxic impurity controls (ICH M7) where required.
- Validate polymorph/salt form confirmation methods (commonly XRPD/DSC and related acceptance criteria).
Which manufacturing geographies dominate meclizine hydrochloride API supply?
Supply is distributed across:
- China-based API manufacturing (common for high-volume antihistamine APIs)
- India-based API manufacturing (common for generic API intermediates and final API salt-form steps)
- Europe-based suppliers (less frequently for commodity APIs, more for higher-control niche specs or local supply programs)
Buyer risk lens by geography
- Regulatory inspection exposure history and compliance alignment with FDA/EMA GMP expectations.
- Batch-to-batch impurity control consistency.
- Logistics continuity and lead times.
How does supplier qualification work for meclizine hydrochloride API?
Qualification for meclizine hydrochloride typically includes:
- Document review: cGMP certificate, DMF reference if applicable, process description, and quality agreements.
- Analytical verification: identity, assay, related substances, water content, particle size (if relevant), and dissolution/particle influence for downstream tablets.
- Stability and packaging integrity: especially for hydrochloride salts, moisture control is critical.
- Change control: process parameter changes and notification obligations for ANDA holders.
What formulation and quality constraints affect meclizine hydrochloride suppliers?
Key practical constraints for finished-dose manufacturers include:
- Tablet hardness, friability, disintegration time, and dissolution profiles.
- Moisture sensitivity and storage conditions aligned to the specific product’s stability protocol.
- Consistent salt-form performance for bioavailability equivalence in generic development contexts.
How many supplier options exist for meclizine hydrochloride (API and finished goods)?
Answer: Meclizine hydrochloride has broad generic availability, so supplier counts are typically high at both API and finished-dose levels. The exact number depends on the specific strength/dosage form in your target market and whether you require FDA DMF-linked API sources.
Procurement consequence
- Competitive pricing pressure is common.
- Main differentiators become quality system maturity, supply continuity, and responsiveness rather than IP exclusivity.
Which suppliers are best positioned for contract manufacturing of meclizine hydrochloride tablets?
Best-fit suppliers for contract manufacturing generally have:
- Multi-product solid dose capacity (tablets/capsules)
- Strong regulatory inspection record
- Robust tech transfer capability
- Equipment suited for antihistamine salt formulations
- Documented dissolution and impurity control methods
- Ability to produce multiple strengths under the same quality system
What generic entry risks exist for meclizine hydrochloride supply?
For meclizine hydrochloride, generic entry risks are usually low on IP grounds because the active ingredient is established. The main constraints are:
- Manufacturing scale and supply continuity
- Quality excursions and regulatory findings
- Timelines for analytic method validation and tech transfer for new manufacturing sites
Key Takeaways
- Meclizine hydrochloride supply is broad because the drug is long established and widely generic.
- Supplier landscape differs by need: API supply (DMF-linked cGMP producers) versus finished tablets/capsules (ANDA/OTC labelers and contract manufacturers).
- Procurement for meclizine HCl is primarily driven by GMP quality, impurity control, stability performance, and supply reliability rather than exclusivity constraints.
- The most actionable supplier mapping is product-specific: Orange Book listings by NDC/strength/dosage form, then tracing application holders and manufacturing sites.
FAQs
-
How can I identify the API manufacturer behind a specific meclizine hydrochloride NDC?
Use the product’s ANDA/Orange Book entry and trace CMC references that link to DMF numbers, then confirm through CoA/quality agreements.
-
Do meclizine hydrochloride tablets and capsules use the same API suppliers?
Often yes for the API, but finished-dose manufacturers can differ by manufacturing site and labeler, affecting the qualified supplier list.
-
What specs matter most for meclizine hydrochloride API purchasing?
Identity/assay, related substances/impurity profile, residual solvents, water content, and impurity control aligned to the downstream finished-dose target.
-
Which quality issues most commonly disrupt meclizine HCl supply chains?
Batch-to-batch impurity variance, moisture control/stability drift, dissolution inconsistency in tablets, and documentation gaps during tech transfer.
-
Is meclizine hydrochloride protected by current US patent exclusivity that limits new suppliers?
In practice, meclizine HCl is not commonly constrained by active exclusivity in modern generic channels; supply barriers are typically operational and quality-system driven.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA Drug Master Files (DMF) guidance and listing structure. U.S. Food and Drug Administration.
